Infection by the human papillomavirus (HPV) is the main factor of cervical cancer. There are currently three vaccines showing efficacy and safety. In Peru, the Ministry of Health has a program of free vaccination for girls aged 9 to 13 years with two doses of tetravalent vaccine (0 and 6 months), whose national coverage is extremely important to reverse the high morbidity and mortality occurring in our country. Older women and boys since age nine can also be vaccinated on their own. This is the main primary prevention that currently exists and must be complemented with secondary prevention.

The Peruvian Society of Obstetrics and Gynecology has contributed to the development of Gynecologic Oncology in the Peruvian medical community, through papers in The Peruvian Journal of Gynecology and Obstetrics, annual meetings, symposia, precongress courses, courses for residents and other academic activities. The most developed topic in the journal has been cervical cancer, which is the main problem in our country, followed by ovarian and breast cancer.

In this symposium we discuss some current issues in oncological gynecology, such as vaccines against the human papillomavirus (HPV), minimally invasive surgery in gynecological cancer and the preoperative assessment of the adnexal mass. In addition, the most important genetic syndromes are reviewed. The World Health Organization in 2017 has pronounced on vaccines against HPV, declaring them very safe and recommending universal vaccination in girls from 9 to 14 years old (1). This requires physicians in general and especially pediatricians, gynecologists and gynecologists oncologists to know well the information on the safety and efficacy of such vaccines and their proper management, even more so with a national program of vaccination against free HPV by the Ministry of health. It is important that the population receives accurate and clear information about current medical knowledge abou...

Cervical cancer is a public health concern. The human papillomavirus (HPV) vaccine protects against infection with HPV. The vaccine has been shown to be effective in preventing premalignant lesions and cervical cancer, as well as lesions of the vulva, vagina, anal canal, penis, and oropharynx. It has also proven to be cost effective and supports the idea of introducing a national vaccination strategy. The HPV vaccine could be the ideal tool for health systems where secondary prevention has not been successful over time. The implementation of the vaccination program in Peru began in 2011. Currently, in Peru, the indication for vaccination is with the quadrivalent vaccines for 5th grade girls from public and private schools. It is administered in 2 doses, 0-6 months. In 2019, coverage in Peru was 87% (234 535 girls) for the first dose and 78% (211 339 girls) for the second dose.

Gynecologic cancer epidemiology in Peru. National program of promotion and cancer prevention. Role of centers of excellence in the prevention and treatment of cervical cancer. Scientific validity of the arguments against the HPV vaccine. Breast cancer in Peru.